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Equine chorionic gonadotrophin (eCG) is a placental glycoprotein critical for early equine 
pregnancy and used therapeutically in a number of species to support reproductive activ-
ity. The factors in trophoblast that transcriptionally regulate eCGβ-subunit (LHB), the gene 
which confers the hormones specificity for the receptor, are not known. The aim of this 
study was to determine if glial cells missing 1 regulates LHB promoter activity. Here, studies 
of the LHB proximal promoter identified four binding sites for glial cells missing 1 (GCM1) 
and western blot analysis confirmed GCM1 was expressed in equine chorionic girdle 
(ChG) and surrounding tissues. Luciferase assays demonstrated endogenous activity 
of the LHB promoter in BeWo choriocarcinoma cells with greatest activity by a proximal 
335 bp promoter fragment. Transactivation studies in COS7 cells using an equine GCM1 
expression vector showed GCM1 could transactivate the proximal 335 bp LHB promoter. 
Chromatin immunoprecipitation using primary ChG trophoblast cells showed GCM1 to 
preferentially bind to the most proximal GCM1-binding site over site 2. Mutation of site 1 
but not site 2 resulted in a loss of endogenous promoter activity in BeWo cells and failure 
of GCM1 to transactivate the promoter in COS-7 cells. Together, these data show that 
GCM1 binds to site 1 in the LHB promoter but also requires the upstream segment of the 
LHB promoter between −119 bp and −335 bp of the translation start codon for activity. 
GCM1 binding partners, ETV1, ETV7, HOXA13, and PITX1, were found to be differentially 
expressed in the ChG between days 27 and 34 and are excellent candidates for this 
role. In conclusion, GCM1 was demonstrated to drive the LHB promoter, through direct 
binding to a predicted GCM1-binding site, with requirement for another factor(s) to bind 
the proximal promoter to exert this function. Based on these findings, we hypothesize 
that ETV7 and HOXA13 act in concert with GCM1 to initiate LHB transcription between 
days 30 and 31, with ETV1 partnering with GCM1 to maintain transcription.
Keywords: equine, trophoblast, placenta, equine chorionic gonadotrophin, glial cells missing 1, eTV1, eTV7, 
hOXa13
inTrODUcTiOn
Equine chorionic gonadotrophin (eCG) is a heterodimeric glycoprotein critical for early equine 
pregnancy. The primary function of eCG is the rescue of the corpus luteum and luteinization of 
secondary corpora lutea through binding to eLH/CG receptors (1, 2). As a direct consequence of this 
binding, a progesterone-rich environment necessary for early conceptus development is maintained 
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(3). In other species, eCG also has a high affinity for FSH recep-
tors (4, 5). As such, eCG extracted from pregnant mare sera is 
utilized therapeutically in cows and laboratory species to support 
follicle development and reproductive activity (6).
The source of eCG is the specialized terminally differentiated 
binucleate trophoblast cells of the chorionic girdle (ChG), and later 
the unique structures they form in the endometrium, termed the 
endometrial cups (7). Corresponding to the development of the 
ChG between days 30 and 36 of pregnancy, eCG can be detected 
in the sera of pregnant mares from around day 40. Beyond day 
120 of pregnancy, eCG secretion diminishes corresponding to the 
destruction of the endometrial cups (8). While structural modifi-
cations that regulate eCG protein expression and activity are well 
defined (9), surprisingly little is known about the factors that 
initially induce and maintain the expression of eCG transcripts in 
equine trophoblast. In general, glycoprotein hormones are com-
posed of an α-subunit; common to all glycoproteins in a species, 
and a β-subunit; which confers the hormones specificity for its 
receptor. In the equid, however, the β-subunit of equine lutein-
izing hormone (eLH) and eCG are encoded by a single gene (10, 
11), yet demonstrate distinct tissue-specific expression profiles. 
Whereas pituitary specific direct transcriptional regulators of 
eLH, such as steroidogenic factor-1 (SF-1), have been investigated 
(12), to date, no placental specific regulator of LHB expression 
has been identified. In equine pregnancy, the β-subunit of eCG/
LH is shown to demonstrate expression levels 100 times lower 
than that of the α-subunit (13), suggesting LHB is the limiting 
factor in the glycoproteins expression and subsequent activity.
Glial cells missing 1 (GCM1) is a transcription factor first 
identified in Drosophila melanogaster (14) and later defined as 
a member of the mammalian glial cells missing (GCM) family 
of proteins which possess a conserved DNA binding domain, a 
nuclear translocation sequence and two transactivation domains 
(15). In the human placenta, GCM1 is well known for its role in 
binding to the syncytin promoter (16), which in turn initiates 
fusion and formation of syncytiotrophoblast competent of secret-
ing human CG (hCG) (17). Expression profiling of transcription 
factors in equine trophoblast showed GCM1 mRNA expression 
is induced during ChG development (13). The functional role 
of GCM1 in equine trophoblast is not known. Based on the 
similar temporal expression patterns of GCM1 and LHB (13), we 
hypothesized that GCM1 directly regulates LHB via binding to 
the LHB promoter.
The aim of this study was to determine (i) GCM1 protein 
expression in the ChG and (ii) whether GCM1 transcriptionally 




This study was carried out in accordance with the Animals 
(Scientific Procedures) Act 1986 guidelines set by the Home 
Office, United Kingdom. All protocols were approved by the 
Home Office and Ethics Committee of the Royal Veterinary 
College (PL70/6944). Eight mares (Equus callabus) aged between 
3 and 7 years of Dartmoor or Welsh breed were maintained at the 
Royal Veterinary College in a paddock on grass and supplemented 
with hay over the winter. The reproductive cycle was manipu-
lated, and pregnancies were established using standard artificial 
insemination and with ovulation induced using either 1,500 IU 
hCG (Chorulon, MSD Animal Health, Milton Keynes, UK) 
intravenously or 2.1 mg Ovuplant® (Dechra Veterinary Products, 
Shrewsbury, UK) subcutaneously. Ovulation was confirmed (day 
0) and then pregnancies were monitored biweekly and on the day 
of isolation using transrectal ultrasonographic evaluation of the 
reproductive tract. Only those conceptuses confirmed to have a 
normal growth rate and normal anatomical development were 
included in the study.
Tissue collection
Conceptuses were recovered by nonsurgical uterine lavage 
between days 27 and 34 of pregnancy, using established methods 
(18). Conceptuses were microdissected into ChG, allantochorion 
(ALC), chorion, yolk sac (YS), bilaminar omphalopleure, and 
fetus, and tissues immediately snap-frozen in liquid nitrogen.
construction of LHB Promoter constructs, 
gcM expression Vectors, and Transient 
Transfection of immortalized cell lines
The 2,500-bp LHB promoter sequence, obtained from ENSEMBL 
76 genome browser, was annotated with predicted GCM1-
binding sites using Match software (http://gene-regulation.
com) based on TRANSFAC® Public 6.0. Truncated promoter 
constructs of specific lengths were constructed via PCR from 
equine genomic DNA, using primers designed with 5′ Mlu1 
and 3′ Xba1 restriction sites. Primer sequences are available in 
Table S1 in Supplementary Material. PCR amplification was car-
ried out using 15  ng of gDNA, in a 20-µL reaction, composed 
of: 10× PCR buffer, 0.2 mM each deoxynucleotide triphosphate, 
1.5 mM MgCl (Invitrogen), 0.25 µM each primer, and 1.25 µL 
recombinant Taq DNA polymerase (Invitrogen), using Cycling 
parameters: denaturation for 2 min at 94°C, 35 cycles of 30 s at 
94°C, 30 s at 59°C, and 1 min at 72°C, and a final extension step of 
10 min at 72°C. PCR products were visualized by electrophoresis 
on a 1% (wt/vol) agarose gel. PCR products were purified, cloned, 
and sequenced to confirm specificity. Promoter products were 
inserted to the pGL3-basic expression vector, through digest of 
PCR product and vector with Mlu1 and Xba1 and subsequent 
ligation. Vectors were confirmed by Sanger sequencing. For 
mutation of the proximal two GCM1-binding sites, gBlocks® gene 
fragments (Integrated DNA Technologies) were designed with a 
2-bp mutation introduced to the site of interest and were cloned 
into expression vectors using 5′ Mlu1 and 3′ Xba1 restriction sites 
as described above.
A GCM1 expression vector was constructed via PCR ampli-
fication of the full length GCM1 gene from day 34 equine ChG 
cDNA and PCR conditions described above. GCM1 cDNA PCR 
products were cloned into the pCMV-myc expression vector (gift 
from Dr. Steve Allen, Royal Veterinary College) via subcloning 
into the Zero Blunt II® TOPO® vector (Invitrogen) via the manu-
facturers’ instructions. The pCMV-Myc vector and Zero Blunt 
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II® TOPO®-GCM1 were subjected to digest with XbaI and KpnI 
restriction enzymes and subsequent ligation with T4 DNA ligase.
Immortalized cell lines, BeWo Choriocarcinoma (BeWo) and 
COS7, were cultured in Dulbecco’s modified Eagle’s-medium 
(DMEM) supplemented with 10% fetal bovine serum, penicil-
lin–streptomycin and l-glutamine, at 5% CO2 at 37°C. Cells were 
transiently transfected using Lipofectamine 2000 transfection rea-
gent (Invitrogen) via the manufacturers’ instructions. Cells were 
transfected in 24-well plates, at a confluency of 80%, with each of 
four LHB promoter inserts or mutant promoter constructs, alone 
or in combination with concentrations of pCMV-myc-eqGCM1 
(0–150 ng), with DNA input controlled with an empty control 
pCMV-myc vector. Renilla was co-transfected as an internal 
control at a concentration of 0.05 ng per well. Twenty-four hours 
post-transfection (selected following a preliminary time course 
experiment), cell lysates were harvested and promoter activity was 
measured using the Dual-luciferase® Reporter Assay (Promega, 
USA), as per the manufacturer’s instructions.
culture Primary chg Trophoblast
Chorionic girdle trophoblast cells were isolated and cultured 
from day 34 ChG tissue obtained from conceptuses as mentioned 
in Section “Tissue Collection.” In DMEM, ChG trophoblast cells 
were gently removed from basement membrane and underly-
ing avascular mesodermal cell layer and cultured as previously 
described (18).
rna isolation and cDna synthesis
Total RNA was isolated from snap-frozen equine ChG and chorion 
tissues, using an RNeasy kit (Qiagen) as per the manufacturer’s 
instructions. RNA (500  ng) was DNase I-treated (Invitrogen), 
and first-strand cDNA synthesis was performed using Moloney 
murine leukemia virus reverse transcriptase (US Biochemical 
Corp) as per the manufacturer’s guidelines.
Quantitative rT-Pcr
Quantitative RT-PCR of equine LHB, GCM1, or the housekeeper 
gene Succinate Dehydrogenase Complex, Subunit A, Flavoprotein 
(SDHA) (13) was carried out using SYBR Green chemistry 
(KAPA SYBR FAST Universal qPCR kit; KAPA Biosystems) with 
a C-1000 thermal cycler and CFX-96 Real time system (Bio-Rad 
Laboratories), in a total volume of 20  µL. Cycling conditions 
were: 38 cycles of 30 s at 95°C, 30 s at 60°C, and 20 s at 72°C. 
Post amplification, a melting curve was run from 60 to 95°C. 
Expression of LHB and GCM1 mRNA in days 27–34 ChG and 
chorion tissues was calculated relative to day 27 ChG expression, 
using the Pfaffl method (19), taking into account the efficiency of 
the reaction for each gene and normalizing to SDHA expression. 
Primer sequences and reaction efficiencies can be found in Table 
S2 in Supplementary Material.
Western Blot analysis of Protein 
expression
Protein was extracted from day 34 equine conceptus tissues by 
grinding and lysing on ice in lysis buffer, composition: 150 mM 
sodium chloride (Sigma), 1.0% Nonidet P-40 (Sigma), 0.5% 
sodium deoxycholate (Sigma), 0.1% sodium dodecyl sulfate 
(SDS, Sigma), 50 mM Tris (Sigma), pH 8.0, 1 mM phenylmethyl-
sulfonyl fluoride (PMSF, Sigma). Protein was extracted from 
BeWo cells and COS7 cells, untransfected or transfected with 
pCMV-myc-GCM1 expression vector, using 50  µl lysis buffer, 
composition: 2% SDS, 2 M Urea (Sigma), 8% sucrose (Sigma), 
20 mM sodium β-glycerophosphate (Sigma), 1 mM sodium fluo-
ride (NaF, Sigma), and 5 mM sodium orthovanadate (Na2VO4, 
Sigma). Cells were scraped from wells and protein extracted 
using a Qiashredder column (Qiagen). Protein concentrations 
were determined using Bradford assay (Bio-Rad Laboratories). 
A total of 50  µg of protein per well was loaded and separated 
by SDS-PAGE on a 10% (wt/vol) polyacrylamide gel before 
being transferred to a Polyvinylidene fluoride membrane via wet 
transfer. Following activation in methanol and blocking for 1 h 
in Tris-buffered saline-Tween 20 (TBS-T) containing 5% (wt/vol) 
nonfat milk, membranes were incubated overnight at 4°C in a 
1:1,000 dilution of rabbit anti-human GCM1 polyclonal antibody 
(Aviva Systems Biology), in TBS-T containing 5% (wt/vol) nonfat 
milk. Antibodies were optimized for specificity to horse GCM1 
protein using COS7 cells transfected with equine GCM1 and 
untransfected control cells (data shown in results). Membranes 
were incubated for 2 h with a 1:10,000 dilution of goat antirabbit 
IgG secondary antibody conjugated to horseradish peroxidase 
(Sigma) in TBS-T containing 5% (wt/vol) nonfat milk. GCM1 
protein was visualized by incubating membranes with ECL plus 
detection reagents (PerkinElmer) and exposure onto Hyperfilm 
ECL. As a loading control, membranes were stripped and rep-
robed for β-actin using a monoclonal mouse β-actin antibody 
(Sigma) at a dilution of 1:5,000. Densitometry analysis of western 
blots was carried out using ImageJ 1.47b software.
chromatin immunoprecipitation (chiP)
Chromatin ImmunoPrecipitation was carried out using the 
Chip-IT® high sensitivity kit (Active Motif) via the manufactur-
ers’ instructions. In brief, primary passage 1 equine day 34 ChG 
trophoblast cells were treated with paraformaldehyde to cross 
link protein–DNA complexes. Cells were ruptured via dounce 
homogenization and chromatin sheared using Micrococcal 
Nuclease (NEB) at a concentration of 1,400  U/μg chromatin. 
Sheared chromatin was incubated overnight at 4°C with an 
antihuman GCM1 antibody (Aviva Systems Biology) conjugated 
to protein G agarose beads and was subjected to column pre-
cipitation. Following reversal of crosslinks and DNA purification, 
qRT-PCR was carried out using primer pairs specified in Table 
S3 in Supplementary Material to assess enrichment of binding of 
GCM1 to predicted GCM1 binding sites in the LHB promoter. 
Data were expressed as enrichment of binding compared to a 
control region of the genome within the coding region of the LHB 
gene with no predicted GCM1 binding sites within 500 bp.
statistical analysis
Statistical analysis was carried out using GraphPad PRISM® V6.02 
with the exception of gene expression data for GCM1 and LHB, 
which was analyzed using SPSS (IBM Analytics). Luciferase assay 
data for basal promoter activity in BeWo and COS7 cells were 
subject to ordinary one-way ANOVA, with Dunnett’s multiple 
FigUre 1 |  GCM1 is expressed in equine trophoblast and expression correlates with LHB. (a) mRNA expression of LHB in ChG and chorion tissues at days 27, 
30, 31, and 34 of pregnancy. (B) mRNA expression of GCM1 in ChG and chorion tissues at days 27, 30, 31, and 34 of pregnancy. (c) Correlation of mRNA 
expression of LHB and GCM1 in individual ChG tissues. ***p < 0.001, ****p < 0.0001 relative to day 27 ChG, ###p < 0.001, ####p < 0.0001 relative to CH at same 
time point (linear mixed-effects modeling, SPSS). (D) Glial cells missing 1 (GCM1) protein expression in untransfected COS7 cells and COS7 cells transfected with 
250 ng of equine pCMV-myc-GCM1 expression vector. B-Actin expression was used as a loading control. (e) GCM1 and B-Actin protein expression in primary 
equine day 34 conceptus tissues: chorionic girdle (ChG), chorion (CH), allantochorion (ALC), and yolk sac (YS).
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comparisons post hoc test. Luciferase assay data for transactiva-
tion studies were subject to ordinary two-way ANOVA, with 
Tukey’s multiple comparisons post  hoc test. ChIP data were 
subject to ordinary one-way ANOVA, with Dunnett’s multiple 
comparisons post hoc test. Gene expression data for GCM1 and 
LHB, from qRT-PCR, was performed using Linear Mixed-Effects 
Modeling in SPSS. In all cases, p ≤ 0.05–0.0001 was accepted as 
statistically significant.
All storage of biological material and laboratory protocols 
conformed to biosecurity and safety measures as set out in the 
Royal Veterinary College code of Good Laboratory Practice.
resUlTs
gcM1 expression in the early equine 
conceptus
To confirm GCM1 as a candidate for eCGB gene regulation, the 
relative expression profiles of LHB and GCM1 mRNA in the ChG 
and chorion (control) tissues from conceptuses at days 27, 30, 31, 
and 34 were quantified using qRT-PCR (n = 4 each time point 
and each tissue). This 7-day period in early equine pregnancy (of 
340-day gestation period) represents the window of initiation of 
chorionic gonadotrophin expression in the mare and is analogous 
to early chorionic development in mouse and human placental 
development. No change in LHB and GCM1 mRNA expression 
was observed in the chorion (Figures  1A,B). When compared 
with day 27, LHB mRNA expression in the ChG increased signifi-
cantly by day 31 of pregnancy (93-fold, p < 0.0001) with further 
increased expression observed at day 34 (5,947-fold, p < 0.0001). 
Expression of LHB was 49-fold higher (p < 0.0001) in day 31 ChG 
and 5,808-fold higher (p < 0.0001) in day 34 ChG both compared 
to time-matched chorion (Figure 1A).
GCM1 mRNA expression was highest within the developmental 
time-frame studied in day 34 ChG (100-fold, p ≤ 0.0001) when 
compared to day 27 ChG expression. A significant increase in 
GCM1 expression was also observed at day 30 (11-fold, p = 0.002) 
and day 31 (24-fold, p < 0.0001) compared to day 27 ChG, thus pre-
ceding the increase in eCGB expression by 24 h. GCM1 expression 
was also significantly increased compared to time matched chorion 
at all time points (day 30: 7.2-fold, p = 0.0013; day 31: 10.1-fold, 
p = 0.0009; day 34: 14.7-fold, p < 0.0001) (Figure 1B). In individual 
ChG tissues, LHB and GCM1 mRNA expression was correlated 
with a correlation value R2 = 0.552 (p = 0.0049) (Figure 1C).
Western blot analysis was used to confirm GCM1 protein 
expression in equine ChG. First, to validate that the antihuman 
GCM1 monoclonal antibody was also able to detect the equine 
protein, COS-7 cells were transfected with an equine GCM1 
expression vector (pCMV-myc eqGCM1). Following transfec-
tion, COS-7 cells expressed equine GCM1 protein as shown by 
a single band of expected size, 49 kDa (Figure 1D). This band 
was not observed in control untransfected COS-7 cells. GCM1 
protein expression in day 34 ChG was subsequently confirmed 
(Figure  1E), with expression also detected in the surrounding 
fetal membranes, ALC and YS (n = 3).
gcM1 Transactivates the LHB Promoter
Interrogation of the proximal 2,500  bp of the LHB promoter 
sequence identified four potential binding sites for GCM1 
(Figure S1 in Supplementary Material) all with 100% match of 
FigUre 2 | Glial cells missing 1 (GCM1) transactivates the LHB promoter. (a) Western blotting of protein extracted from human choriocarcinoma BeWo cells (n = 3) 
using an antihuman GCM1 monoclonal antibody (c-terminal). β-actin was used as a loading control. (B) BeWo cells were transfected with specific lengths of the 
LHB promoter in a pGL3-basic luciferase reporter vector (n = 3). Activity of promoter constructs was expressed as fold-change firefly/renilla compared to 
pGL3-basic. **p < 0.01, ***p < 0.001 (one-way ANOVA). (c) pGL3-basic and pGL3-335 were co-transfected with ratios of pCMV-myc-Empty: pCMV-myc-GCM1 to 
assess ability of GCM1 to drive promoter activity in COS7 cells (n = 3). *p < 0.05, ***p < 0.001, ****p < 0.0001 relative to pGL3-335 alone, ##p < 0.01 relative to 
pGL3-335 + 250 ng pCMV-myc-Empty, ^^^p < 0.001 relative to pGGl-335 + 150 ng pCMV-myc-GCM1 (two-way ANOVA). (D) Specific lengths of the LHB promoter 
were transfected with 150 ng of empty pCMV-myc-Empty vector, or with 150 ng of pCMV-myc-GCM1 (n = 4). *p < 0.05, **p < 0.0.01, ***p < 0.001, ****p < 0.0001 
(two-way ANOVA).
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the known core binding sequence GCGG and a matrix similarity 
greater than 80%. Sites were located at positions (1) −87 to −98 
(Mat.Sim. = 0.903, binding sequence 5′-agccTGCGGgtat-3′), (2) 
−124 to −136 (Mat.Sim. =  0.865, binding sequence 5′-gccaT-
GCGGgcat-31), (3) −779 to −791 (Mat.Sim. =  0.869, binding 
sequence 5′-ccgcTGCGGggcc-3′), and (4) −2055 to −2067 (Mat.
Sim. = 0.957, binding sequence 5′-attcTGCGGgggg-3′) relative 
to the translational start site and predicted to bind to the negative 
strand of DNA.
As equine trophoblast cell lines are not available, in  vitro 
experiments to interrogate the activity of the LHB promoter were 
performed using human BeWo choriocarcinoma trophoblast 
cells. Western blotting confirmed the BeWo cells expressed GCM1 
(n = 3) (Figure 2A). Bioinformatic analysis showed human and 
equine GCM1 protein sequences were 79% homologous and 
highly homologous in the DNA binding domain (94.5%) (Figure 
S2 in Supplementary Material). Truncated LHB promoter con-
structs as represented in Figure 2B were designed to encompass 
between 1 and 4 predicted GCM1-binding sites and transfected 
into BeWo cells. Luciferase assays assessing basal LHB promoter 
activity demonstrated that only the pGL3-335 and pGL3-1888 
promoter constructs were active above background activity of 
pGL3-basic alone (n = 3) (Figure 2B).
In order to assess transactivation of the LHB promoter by 
GCM1, the COS7 cell line (which was shown in Figure 1D to 
not express endogenous GCM1) was co-transfected with LHB 
promoter constructs and our equine GCM1 expression vec-
tor (pCMV-myc-eqGCM1) or an empty vector (pCMV-myc). 
First, the optimal concentration of pCMV-myc-eqGCM1 was 
determined. Addition of a ratio of pCMV-myc-Empty 100:150 
pCMV-myc-eqGCM1 was able to increase promoter activity of 
pGL3-335 26-fold (p = 0.016) over pGL3-335 alone (Figure 2C); 
however, addition of higher ratios of pCMV-myc-eqGCM1 was 
unable to further drive the promoter above the levels of 150 ng 
pCMV-myc-eqGCM1. Next, co-transfection of the four LHB 
promoter constructs with either the pCMV-myc-empty vector 
(150 ng) or pCMV-myc-eqGCM1 (150 ng) showed that GCM1 
transactivated the pGL3-335 construct 3.1-fold (p < 0.0001) over 
pCMV-myc-Empty (Figure 2D). The pGL3-1888 construct (1.9-
fold, p = 0.0002) and pGL3-2157 construct (1.8-fold, p = 0.004) 
were both significantly driven by pCMV-myc-eqGCM1 
when compared with pCMV-myc-Empty. Addition of 
FigUre 3 | Glial cells missing 1 (GCM1) binds to the proximal LHB promoter in primary equine chorionic girdle (ChG) trophoblast cells and mutation of GCM1 site 1 
results in loss of promoter activity. (a) Chromatin ImmunoPrecipitation was carried out on formaldehyde fixed chromatin complexes from passage 1 day 34 primary ChG 
trophoblasts, using an antihuman GCM1 antibody for immunoprecipitation. Binding of GCM1 to predicted GCM1-binding sites was expressed as fold-change 
enrichment over binding to a control region within the coding sequence of the LHB gene (n = 2 conceptuses). (B,c) The two GCM1-binding sites in the pGL3-335 
promoter construct were mutated. Red boxes depict GCM1 binding sites. Red box with a cross depicts a mutated site. Wild-type pGL3-335 and its two mutant 
constructs, pGL3-335-mut1 and pGL3-335-mut2, were co-transfected (B) into BeWo cells (n = 3) (c) into COS7 cells, with 150 ng of pCMV-myc-GCM1 or pCMV-myc-
Empty as a control (n = 4). Promoter activity was assessed by luciferase assay. *p < 0.05, **p < 0.01, ****p < 0.0001 [(B) one-way ANOVA, (c) two-way ANOVA].
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pCMV-myc-eqGCM1 did not drive activity of the 119-bp insert 
containing the most proximal site 1 GCM1-binding site.
gcM1 Binds the LHB Promoter via 
interaction With the Proximal gcM1 
Binding site
In order to determine whether GCM1 drives LHB promoter activ-
ity through direct binding to one or more of the binding sites, ChIP 
was performed using formaldehyde fixed chromatin complexes 
from passage one day 34 primary equine ChG trophoblast cells 
(n = 2 conceptuses) and the previously validated cross reactive anti-
human GCM1 antibody (Figure 1D) (Figure S3 in Supplementary 
Material). Quantitative RT-PCR was then carried out using primers 
designed against GCM predicted binding sites 1–3 and a control 
site within the coding region of the LHB gene with no predicted 
GCM1-binding sites within 500 bp. There was minimal binding in 
the control amplified region. Amplification of the promoter region 
flanking GCM1-binding site 1 identified enriched binding in this 
region when compared to the control region of the LHB gene 
(164-fold, p = 0.054, Figure 3A). There was modest enrichment 
of binding in GCM1 binding site 2 (Figure 3A). The PCR reaction 
for binding site 3 failed to amplify a product.
To confirm that GCM1 transactivates the LHB promoter via 
binding to site 1, a 2 base pair mutation was introduced into 
the core-binding site of GCM1 sites 1 and 2. Inserts were then 
transfected into BeWo cells to determine endogenous promoter 
activity (n = 3). Mutation of GCM1 binding site 1 rendered the 
pGL3-335 promoter inactive in BeWo cells, with no change in 
activity compared with pGL3 basic (Figure 3B). The pGL3-335-
MUT2 construct, with disruption of binding site 2, remained 
significantly active above pGL3-basic with similar activity to 
the intact construct, pGL3-335 (Figure  3B). Inserts were then 
transfected into COS7 cells alone or with pCMV-myc-eqGCM1 
to determine whether mutation of binding sites 1 and 2 disrupted 
the ability of GCM1 to transactivate the LHB promoter (n = 4). 
Consistent with the results in BeWo cells, pCMV-myc-eqGCM1 
transactivated pGL3-335 and pGL3-335MUT2 but failed to 
significantly transactivate pGL3-335-MUT1 (Figure 3C).
Other Transcription Factors are Proposed 
to regulate LHB
Results above indicate that GCM1 binds to GCM1 binding site 
1 located within 119 bp of the translational start site but activ-
ity also required the upstream segment of the CGB promoter 
FigUre 4 | Glial cells missing 1 (GCM1) binding partners are differentially expression in vivo during differentiation of chorionic girdle (ChG) trophoblast cells. (a) 
mRNA expression of ETV1, ETV7, HOXA13, and PITX1 in ChG and chorion tissues between days 27 and 34 of pregnancy, as determined by microarray analysis 
(n = 4). *p < 0.05, **p < 0.01, ***p < 0.001 relative to day 27 ChG, #p < 0.05, ##p < 0.01, ###p < 0.001, relative to time matched chorion. (B) Schematic of the LHB 
promoter showing directly bound GCM1-binding site and region of potential binding by other transcription factors. TLSS is translational start site, TSS shown by 
black arrow is transcriptional start site. Numbers are relative to TLSS.
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between −119 and −335. This suggested that another factor or 
factors may act in concert with GCM1. Recently, a number of 
new specific transcription factor-transcription factor interactions 
were identified including 14 proteins found to form DNA binding 
complexes with GCM1 (20). Next, we interrogated microarray 
data generated in the laboratory as part of another project (GEO: 
GSE113072) to determine whether these 14 GCM1 binding 
partners were differentially expressed in the ChG between days 
27 and 34. Twelve of the genes were represented in the microarray 
with 7/12 genes differentially expressed (n = 4, fold-change > 2 
relative to day 27 ChG, FDR p < 0.05) during ChG development: 
ETV1, ETV7, HOXA13, PITX1, HOXB13, ONECUT2, and ELK3.
The four genes with the greatest magnitude of differential 
expression in the ChG between days 27 and 34 expression were 
ETV1, ETV7, HOXA13, and PITX1 (Figure 4A). ETV1 expres-
sion did not differ significantly over time or between tissues until 
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day 34 of pregnancy. At day 34 of pregnancy ETV1 expression was 
9.4-fold greater in the ChG than day 27 ChG (p = 0.0008). ETV7 
expression rose significantly by 3.6-fold by day 30 of pregnancy 
in the ChG compared to day 27 ChG (p =  0.003). Expression 
remained transiently increased at day 31 of pregnancy (4.2-fold, 
p = 0.001) before returning to expression levels comparable to 
that at day 27 by day 34 (Figure 4A). HOXA13 mRNA expression 
also increased significantly in the ChG at day 30, remaining tran-
siently increased at day 31 and decreasing at day 34 to expression 
comparable to day 27 ChG. PITX1 expression decreased in the 
ChG over the time course with expression 1.6-fold lower in the 
ChG at day 31 (p = 0.024) and 4.2-fold lower in the ChG at day 34 
(p = 0.0019), compared to the day 27 ChG. Expression remained 
unchanged in the chorion for all four genes (Figure 4A).
DiscUssiOn
Here, we show for the first time regulation of LHB appears to 
be under the control of direct binding of GCM1 to a GCM1-
binding site immediately proximal to the transcription start site. 
Expression of GCM1 at the mRNA and protein level, combined 
with its confirmed correlation to LHB expression between days 27 
and 34 of pregnancy in the ChG are all consistent with this role. 
Regulation of LHB by GCM1 is predicted, however, to require 
a co-operative binding of another transcription factor within 
the promoter region between 119 and 335  bp upstream of the 
TLSS. GCM1-binding partners, ETV1, ETV7, and HOXA13 were 
found to be induced in the ChG around the time of initiation 
of LHB expression and as such are excellent candidates for this 
role. Figure 4B demonstrates schematically the understanding of 
LHB promoter regulation as described within this study. It is of 
note that developmental stages beyond day 34 may offer further 
insight into regulation of maintenance of eGC expression.
Glial cells missing 1 was first proposed as a candidate for regu-
lation of LHB expression based on previous data obtained in the 
ChG (13), whereby GCM1 mRNA expression increased through 
pregnancy days 27–34, at the time of trophoblast differentiation 
and increase in eCG production. Expression data presented in 
this present study was fully supportive of these observations, 
confirming GCM1 expression in the ChG increased significantly 
sevenfold by day 30 of pregnancy compared to day 27, thus 
preceding the increase in expression of LHB observed from day 
31 of pregnancy. In addition, expression of GCM1 and LHB in 
individual ChG tissues was found to be highly correlated. The 
early increase in GCM1 expression, relative to the increase in LHB 
expression, and the correlation of expression profiles, is consist-
ent with a role for GCM1 to transcriptionally regulate CG/LHB. 
This was strengthened further by bioinformatics analysis of the 
GCM1 protein, which confirmed equine GCM1 to be structurally 
similar to its human homolog, a known placental specific tran-
scription factor (21, 22). Like human GCM1, the equine protein 
has a placental specific expression profile and contains the highly 
conserved N-terminal DNA binding domain, characteristic of all 
GCM family proteins (13, 23).
Prior to this study, translation of GCM1 into protein within 
the ChG had not been demonstrated. Data here showed that at 
day 34, GCM1 protein is expressed by the ChG, as well as in the 
surrounding conceptus tissues; the chorion and ALC. This is 
reminiscent of the protein expression profile observed in both 
human and mouse placenta. In the murine placenta, GCM1 
expression is confined to clusters of trophoblast cells of the cho-
rion and later to the labyrinth, formed upon fusion of the allantois 
to the chorion (24). The ChG of the equine placenta originates 
from cells of the chorion and sits in contact with the ALC (7, 
25), therefore expression of GCM1 observed in these tissues is in 
agreement with the expression observed in the mouse and human 
placental counterparts.
Glial cells missing 1 exerts its regulatory effects upon the LHB 
promoter via direct binding to a GCM1-binding site located 
between 87 to 98 bp upstream of the TLSS. Through co-trans-
fection studies, mutation of the most proximal GCM1-binding 
site to the TLSS in the LHB promoter was shown to ablate the 
ability of GCM1 to drive the proximal 335 bp LHB promoter; the 
promoter region shown to be most responsive to GCM1 in vitro. 
ChIP studies demonstrated direct binding of GCM1 to this proxi-
mal GCM1-binding site. The observation that GCM1 is a direct 
regulator of LHB is consistent with the known role for GCM1 as 
a regulator of hCGB (26). It is thought that production of hCG by 
the syncytiotrophoblast of the human placenta causes an increase 
in intracellular cAMP, thus activating the protein kinase A (PKA) 
signaling pathway, which leads to further trophoblast fusion and 
hCG production. Activation of the PKA signaling pathway causes 
phosphorylation and subsequent stabilization of GCM1, which 
has been shown to directly bind to the proximal promoter of the 
hCGB gene in a feedback loop (26). Therefore, it is possible, taking 
into account the findings of this study and recent identification 
of a possible syncytin homolog in equine placenta (27), that a 
similar feedback regulation may occur in the equine trophoblasts, 
potentially explaining the correlation between LHB and GCM1 
mRNA expression and the steep increase in expression of both at 
the mRNA level between days 31 and 34 of pregnancy.
Glial cells missing 1 is the first transcription factor identified to 
regulate the LHB subunit in the equine placenta. Although some 
placental specific regulators of the equine glycoprotein α-subunit 
have been identified, including ATF and TSEB (12), the only stud-
ies surrounding the equine β-subunit focus on pituitary specific 
expression of eLHB in human pituitary cell lines (12). SF-1 was 
found to regulate activity of the eLHβ promoter in gonadotrope 
cell lines, but to be non-essential to basal promoter activity. The 
site of initiation of transcription of hCGB is 366 bp upstream of 
that for hLHB (12), resulting in distinct promoters for pituitary 
LHβ and placental CGβ and, therefore, different regulatory 
elements. In the equid the site of initiation, are identical for both 
genes (12). With SF-1-binding sites predicted by Wolfe (12) to be 
within the 335 bp proximal promoter, it is plausible SF-1 could 
also be a co-regulator of LHB in the placenta but expression 
profiles for SF-1 and promoter activity need to be ascertained. 
Interestingly, these studies also found the β-subunit promoter to 
be inactive in the BeWo cell line (12), a finding contradictory to 
the data presented here. Within this study, the BeWo cell line was 
used as a model for equine trophoblast cells, based on the demon-
stration that the BeWo cells expressed endogenous GCM1, can be 
driven to differentiate to a multinucleate population and produce 
hCG in culture.
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It is possible that GCM1 is not only responsible for regulation 
of LHB expression, but may act upon other gene promoters to 
promote ChG development between days 27 and 34 of pregnancy. 
In the human placenta GCM1 is proven to act as a powerful tran-
scriptional regulator of syncytin, responsible for syncytialisation 
of trophoblast cells and subsequent hCG production (16, 28). 
Human GCM1, therefore, also acts as an indirect regulator of hCG 
production. Its role in syncytium formation is confirmed in mouse 
studies, whereby GCM1-null mice fail to form sufficient placental 
villi (29). It must not be overlooked that, although GCM1 is here 
proven to regulate LHB directly, a conserved role for GCM1 in 
regulation of trophoblast differentiation may also exist. Until 
recently, no equine homolog of syncytin had been identified in 
horse placenta, but recent studies have identified an endogenous 
retrovirus (ERV), with similar properties to syncytin in other 
trophoblast of the equine placenta (27). It is possible that GCM1, 
having been identified here as a direct transcriptional regulator 
of CG/LHB, may play an additional role in ChG development, 
through transcriptional regulation of ERV expression. Studies to 
assess the aforementioned ERV expression in the ChG and possible 
interaction of GCM1 would be required to address this hypothesis.
Data obtained to date are strongly indicative of a role for 
one or more co-factors interacting with GCM1 to regulate LHB 
expression. Although binding of GCM1 to the most proximal 
binding site to the TLSS was confirmed in immunoprecipitation 
studies, presence of only this binding site, within the 119  bp 
proximal promoter, was not sufficient for GCM1 transactivation 
of promoter activity. The enhanced promoter activity of the 
335 bp promoter construct over the 119 bp promoter construct is 
suggestive of a key transcriptional activator within the promoter 
region between −119 and −335 bp relative to the TLSS. However, 
disruption of GCM1 binding to the predicted binding site within 
this region (Site 2) had little effect upon GCM1’s ability to drive 
LHB promoter activity. Driving of the LHB promoter by GCM1, 
both endogenously in BeWo cells and in transactivation studies 
in COS7 cells, was only significantly reduced by deletion of the 
most proximal GCM1-binding site, within the 119 bp promoter. 
GCM1 is, therefore, almost certain to require interaction with 
another transcription factor, or factors, which bind somewhere 
between 119 and 335 bp of the TLSS in order to exert its regula-
tion upon the LHB promoter.
It is known that transcription factors often interact with other 
factors, in complexes, to alter DNA binding specificity or enhance 
transcription (30). Studies by Jolma et al. (20) identified a large 
number of transcription factors to interact with GCM1 in this 
way to bind and regulate gene promoters. The theory for existence 
of a co-regulator of LHB may be further supported by the basal 
activity of the 335 bp and 2,157 bp LHB promoter constructs in 
the COS7 cell line. COS7 cells were shown to express no GCM1 
at the mRNA or protein level; therefore, another factor must be 
acting upon the promoter inserts to drive basal promoter activity 
in this cell line. Identification of other transcription factors which 
directly bind to and regulate activity of the LHB promoter is a 
major area of future study to increase our comprehension of eCG 
production by ChG trophoblast cells.
In summary, here we have demonstrated that GCM1 is a 
direct transcriptional regulator of LHB in ChG cells of the equine 
placenta. A number of key questions have arisen from the data, 
investigation of which is integral to a fuller understanding of the 
transcriptome of ChG trophoblast cells, ChG development, and 
eCG production. Further studies are required to determine the 
possible role of GCM1 binding partners play in LHB regulation.
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FigUre s1 | The CGB promoter contains four possible glial cells missing 1 
(GCM1)-binding sites. The 2,500-bp LHB promoter sequence was obtained from 
ENSEMBL genome browser and Match software was used to identify GCM1 
consensus binding sites with a core sequence match of 1 and matrix similarity 
>0.8. The four consensus-binding sites (underlined in red) for GCM1 are located 
at positions (1) −87 to −98 (2) −124 to −136 (3) −779 to −791 and (4) −2055 to 
−2067, relative to the translational start site. Arrow depicts transcriptional start 
site at −70 bp, and ATG depicts translational start site. Numbers on diagram are 
relative to translational start site.
FigUre s2 | Structure of the glial cells missing 1 (GCM1) family. Shown is 
human GCM1, located on chromosome 6. The coding region of glial cells 
missing spans exons 2 to 6 in the genomic sequence. Nucleotide position 
numbers show start and finish of coding region. The protein consists of a 
conserved N-terminal DNA binding domain, underlined in red on the cross-
species alignments, a nuclear localization sequence and two C-terminal 
transactivation domains. The C-terminal region shows poor species 
conservation. Seven conserved cystein residues are shown with black arrows.  
* denotes conserved amino acids, : denotes interchangeable amino acids 
properties, and · denotes amino acids with similar properties.
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FigUre s3 | ChIP was carried out on formaldehyde fixed chromatin 
complexes from passage 1 day 34 primary chorionic girdle trophoblasts, using 
an antihuman glial cells missing 1 (GCM1) antibody for immunoprecipitation. 
Binding of GCM1 to predicted GCM1-binding sites was determined using PCR 
and primers designed to detect sites, 1–4 and two control sites that were not 
predicted GCM1 binding sites within 500 bp (n = 2 conceptuses). Only sites 
1–3 and one control site were taken forward to quantitative RT-PCR shown in 
Figure 3a.
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